Nanodropper

The Nanodropper Adaptor has been clinically shown to reduce eyedrop size by over 60% without compromising efficacy in lowering intraocular pressure for glaucoma and ocular hypertension patients. Clinical trial results published in Ophthalmology demonstrated non-inferiority compared to conventional drops and suggested reduced systemic side effects such as heart rate decrease. The study's findings indicate that there was no clinically significant difference in intraocular pressure (IOP) when administering microdrops from the Nanodropper® Adaptor compared to conventional eyedrops of the glaucoma treatment timolol maleate 0.5%. The product has received FDA listing and multiple awards for innovation.